tigsun covid-19 combo igm/igg rapid test (lateral flow method) is an immunochromatographic assay for rapid, qualitative detection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) igm/igg antibodies in human whole blood, serum and plasma samples; this test is to be used as an aid in the clinical diagnosis of coronavirus infection disease (covid-19), which is caused by sars-cov-2.
2019 novel coronavirus, now known as sars-cov-2 (previously known as 2019-ncov), is a new β-type coronavirus, which is a single-stranded rna virus that can cause human respiratory infections. its genetic characteristics are significantly different from severe acute respiratory syndrome (sars)-associated coronavirus and middle east respiratory syndrome (mers)-associated coronavirus. the main infection site of the sars-cov-2 is the lower respiratory tract, which has a higher incidence in the elderly. the incubation period of infection is variable. common symptoms after infection with sars-cov-2 include respiratory symptoms, fever, cough, shortness of breath, and difficult breathing. in more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure, and even death. the who has named the disease caused by sars-cov-2 as coronavirus disease 2019 (abbreviated “covid-19”). sars-cov-2 is highly contagious and mainly transmitted through contact, droplet or airborne routes.